TickerTalks
Browse all tickers →
TickerTalks›$HLP
HLHLP

Hongli Group Inc.

$HLP·$165M·Steel·Basic Materials
$2.57+1.2%YTD+144.2%1Y+71.6%
Price updated 4m ago·X counts updated 5d ago
HLHLP
$HLPHongli Group Inc.
$2.57+1.16%33 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $HLP on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

33X posts · last 7 days
Sep 20Sep 27
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $HLP's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 52% of tracked names.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $HLP — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-10-01

The move is getting stronger, with heavier trading behind it.

Microcap Chinese steel-cold-formed-sections name up 142% YTD, 96% of 52-week range, +72% above 50-day

Hongli Group is a $165M Chinese cold-formed steel sections microcap in an extreme technical setup — up 142% year to date, 96% of 52-week range, trading +72% above the 50-day on no visible company-specific catalyst.

  • 2025 full-year revenue $10.0M (+41% year over year), operating margin 11.5%, EPS $0.013 — tiny absolute numbers; the stock is a liquidity-driven microcap momentum move, not a fundamentals-driven one
  • Trailing P/E 28.4 against a near-zero EPS base is a math artifact; price-to-sales 2.87 on a sub-$10M revenue business is a rich multiple for anything other than extreme growth optionality
  • No sentiment chatter on the equity (the news items are about a different Helus Pharma HLP-003 drug — unrelated company); no insider activity, no scheduled earnings; beta 0.49

The Chinese steel-cold-formed-sections business is a specific niche; the +72% premium to the 50-day is where microcap momentum trades reverse violently. No near-term catalyst to anchor the move, so the risk-reward tilts hard against adding at this technical extreme.

What to watch: Any company-filed 8-K or press release that explains the move (none visible), next scheduled earnings date, and whether the technical pullback from the +72% premium to the 50-day develops.

On the calendar: Not scheduled

sentiment sparseearnings date missing

Read the AI verdict on $HLP

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Chinese manufacturer of cold roll-formed steel profiles for mining, construction, and agricultural equipment, exported to South Korea, Japan, and the U.S.

Industry overviewAI analysisGenerated by AI from underlying data

Where Steel sits in its cycle right now — and what that implies for $HLP.

Steel · Basic Materials

No material change from last week — Hot-rolled coil futures near $1,222/ton sustains EAF mini-mill margin expansion.

What this means for $HLP

Neutral — Chinese manufacturer of cold roll-formed steel profiles for mining, construction, and agricultural equipment, exported to South Korea, Japan, and the U.S.

Top industry ETF

$SLXVanEck Steel ETF
+19.2%YTD
+37.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
28.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
3.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
12.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
3.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
32.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$10.0M+41.4%30.9%11.5%$0.01$1.0M
Q2 FY25$9.6M+7.5%34.3%13.4%$0.01$-376K
Q4 FY24$7.1M-27.1%31.0%1.6%$0.00$881K
Q2 FY24$7.0M-33.6%33.1%-24.3%$-0.15$-1.6M

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.97%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+69.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+143.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 50.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.495-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 12 other (9 6-Ks · 1 D · 1 20-F · 1 NT 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depressionmarketbeat.com·9d agoHelus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026globenewswire.com·12d agoHelus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalystseekingalpha.com·42d agoHongli Group Inc. Announces Compliance with Nasdaq Minimum Bid Price Requirementprnewswire.com·51d agoHelus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Scheduleglobenewswire.com·74d ago

More in Steel

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$CMC$CLF$NUE$STLD
Voices on X · last 7 days

No standout posts about $HLP on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport